Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2954 Target Snapshot

Cathepsin S · SINGLE PROTEIN · Homo sapiens

3,068Compounds
307Assays
4Approved Drugs
3,303.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Cathepsin S shows clinical signal disease relevance led by Sjogren syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P25774. Start with Sjogren syndrome, then reuse UniProt P25774 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with Sjogren syndrome, then reuse UniProt P25774 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
Sjogren syndrome

Cathepsin S shows clinical signal disease relevance led by Sjogren syndrome. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Sjogren syndrome because it currently carries clinical signal support. Linked drugs include PETESICATIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cathepsin S as ChEMBL target CHEMBL2954, mapped to UniProt P25774. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cathepsin S
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2954
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P25774
Cathepsin S
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Cathepsin S is the right protein anchor across sources, using UniProt P25774 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Sjogren syndrome is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelCathepsin S
UniProt AccessionP25774
Component TypeProtein
Sequence Length331 aa

Cathepsin S

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Cathepsin S, mapped to UniProt P25774. Sequence length is 331 aa.

Mapped IDP25774
Review nameCathepsin S
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

Cathepsin S shows clinical signal disease relevance led by Sjogren syndrome. 2 more disease programs remain visible in the same review block.

Clinical signal Phase II
Sjogren syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugPETESICATIB
Clinical signal Phase I
celiac disease
1 linked drug · 1 direct · 1 efficacy
Linked drugPETESICATIB
Clinical signal Phase I
type II hypersensitivity reaction disease
1 linked drug · 1 direct · 1 efficacy
Linked drugPETESICATIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with Sjogren syndrome because it currently carries clinical signal support. Linked drugs include PETESICATIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseSjogren syndrome
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
2
Phase III
9
Phase II
Assay Mix

Activity Type Distribution

IC502,382.0
KI852.0
EC503.0
KD66.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5573840 10.8 Ki 0.016 Preclinical
CHEMBL3651506 10.54 IC50 0.029 Preclinical
CHEMBL3651502 10.28 IC50 0.052 Preclinical
CHEMBL3651503 10.25 IC50 0.056 Preclinical
CHEMBL3651507 10.25 IC50 0.056 Preclinical
CHEMBL3651508 10.21 IC50 0.061 Preclinical
CHEMBL4777335 10.05 Ki 0.09 Preclinical
CHEMBL155560 10.0 Kd 0.1 Preclinical
CHEMBL2207565 10.0 IC50 0.1 Preclinical
CHEMBL4297638 10.0 IC50 0.1 Clinical
Distribution

pChEMBL Value Distribution

149
5.0
231
5.5
367
6.0
426
6.5
359
7.0
335
7.5
322
8.0
294
8.5
227
9.0
37
9.5
pChEMBL
Approved Drugs

Approved Drugs

SIMEPREVIR
CHEMBL501849
Approved 2013
BOCEPREVIR
CHEMBL218394
Approved 2011
TELAPREVIR
CHEMBL231813
Approved 2011
Assay Landscape

Assay Landscape

307
Total Assays
2,732
Tested Compounds
4
Assay Types
Binding — 292 assays, 2,732 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 236 2,291 7.2
cell-based format 36 199 6.6
assay format 20 242 7.4
ADME — 9 assays, 9 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 9 9 6.2
Functional — 5 assays, 4 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 5 4 7.6
Toxicity — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 7.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine